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ABSTRACT
Introduction: Nebulizers used to deliver aerosol
during non-invasive mechanical ventilation
(NIV) have many types, each type has many
different designs. This study aimed to deter-
mine the effect of nebulizer deign on aerosol
delivery in NIV.
Methods: Different designs of jet nebulizer (JN)
and vibrating mesh nebulizer (VMN) were tes-
ted by placing 1 ml of salbutamol in a nebulizer
chamber operated in an in vitro NIV setting
using a breathing simulator with adult settings
(inhalation–exhalation ratio 1:3, 15 breaths/
min and tidal volume 500 ml) and mechanical
ventilator (MV) set at spontaneous mode with a
peak inspiratory pressure of 20 cm H2O and a
peak expiratory pressure of 5 cm H2O. Inhala-
tion filters were placed before the breathing
simulator to collect emitted aerosol (inhalable
dose). Also, amounts of drug left in nebulizer
chamber (residual dose) were collected and
analyzed for salbutamol content. Statistical data
analysis and modeling was performed on the
results.
Results: The vibrating mesh nebulizer deliv-
ered significantly higher inhalable doses and
lower residual dose compared to JN (p\0.001).
Inhalable doses of salbutamol and residual dose
differed significantly (p\0.05) for different
designs of JN. Delivery via VMN was not affec-
ted by the difference in designs. Data modeling
showed no change by changing VMN type but
changing JN type resulted in a sharp change in
the inhaled and residual doses.
Conclusions: Nebulizer design has a great role
in efficacy of JN but not VMN and different
types of JN should not considered interchanges
without dose adjustment. Modeling can opti-
mize these results for better aerosol delivery.
Keywords: Fill volume; Modeling; Nebulizer;
Neural networks; Non-invasive mechanical
ventilation (NIV)
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There are three main types of nebulizers (jet,
ultrasonic, and vibrating mesh nebulizer). The
jet nebulizer (JN) is the most commonly used
type [1] due to its low cost, but the main dis-
advantage of JN is its very low percent of emit-
ted drug. Less than 10% of total dose could be
delivered to the patient and in some situations
it could be 5% [2]. This low percent of delivered
dose may affect therapy outcomes of the patient
[3]. This obstacle may be overcome with a
vibrating mesh nebulizer (VMN) [4, 5], which is
expensive, but more efficient in delivery than
the JN [6]. JN and VMN have various brands
with different designs. The jet is operated by air
pressure [6]. Nozzle cover and nebulizer cham-
ber shape or sizes are the main parts that differ
from one jet nebulizer to another [6]. For
vibrating mesh nebulizers, the shape of solution
container (the molding of the nebulizer cham-
ber) is the main difference in design, with the
same vibrating mesh technology.
Delivery of aerosol to mechanically venti-
lated patients using JN and VMN is a widespread
practice. Aerosol delivery in non-invasive ven-
tilation (NIV) was proven to be of benefit and
has been well studied [5, 7–11]. However, the
effect of the change of design of nebulizers with
the same mechanism on delivery has not been
studied much. The aim of this study was
therefore to evaluate the effect of different
nebulizer designs on aerosol delivery to
non-invasive ventilated patients.
METHODS
Three differently brand, with different design,
of JN and another three differently brand, with
different design, of VMN were used in the study.
The JN used were JN A (Hospital and Home
Care, China), JN B (Dolphin Medical, Turkey)
and JN C (Philips Respironics, UK) operated
with an air flow of 6 l/min into the nebulizer to
aerosolize the respirable solution. The VMNs
used were Aerogen Pro [PRO] Nebulizer and
Aerogen Solo [SOLO] Nebulizer (Aerogen Lim-
ited, Galway, Ireland), and NIVO Nebulizer
(Aerogen/Philips, MA, USA). Figure 1 represents
a schematic diagram of the six nebulizers that
were studied.
Each nebulizer with its T-piece was connected
to the NIV in vitro model as shown in Fig. 2. The
NIV in vitro model consisted of a breathing sim-
ulator (5600i, Michigan Instruments, USA) with
adult settings (inhalation: exhalation ratio 1:3, 15
breaths/min and tidal volume 500 ml), ventila-
tion circuit, consistedof a smooth22-mminternal
diameter tubing of 180 cm length, and ventilator
(Nippy2, B and D Electromedical, Warwickshire,
UK). The ventilator was set in spontaneous mode
with a peak inspiratory pressure of 20 cm H2O and
a peak expiratory pressure of 5 cm H2O. A filter
was placed in a filter holder (PariGmbH, Starn-
berg, Germany) fixed before the breathing simu-
lator for collection of inhalable dose from each
nebulizer studied that could be delivered to the
breathing simulator representing the patient.
For each nebulizer, ten runs were performed.
During each run, 1 ml of salbutamol (Farcolin
respirator solution, 5000 lg/ml; Pharco Phar-
maceuticals, Egypt) was placed inside the neb-
ulizer chamber. We chose this small fixed
volume to determine the real effect of the neb-
ulizer design on aerosol delivery since the
residual dose left in the nebulization chamber
differs from one nebulizer to another [12]. The
breathing simulator and ventilator were turned
on 30 s before operating the nebulizers. For JNs,
they were operated until sputter but VMNs were
operated until no vapors were seen in the
T-piece.
Filters were collected and rinsed in 90%
acetonitrile (v/v) and then sonicated and the
nebulizer chamber was rinsed with a constant
volume of 90% acetonitrile (v/v). High-perfor-
mance liquid chromatography (HPLC) with UV
detection was used to determine the amounts of
salbutamol obtained from filters left in the
nebulizer chamber. The method used an Agilent
1260 infinity diode array detector VL (G131SD,
Agilent, USA) set at 225 nm to quantify
amounts of salbutamol. A mobile phase con-
sisted of (90:10 v/v) acetonitrile and water
mixture [containing 0.1% phosphoric acid] was
pumped at flow rate 1 ml/min by Agilent 1260
infinity preparative pump (G1361A, Agilent,
USA), through c18 column (a 25 9 4.6 mm
ZORBAX Eclipse Plus, Agilent, USA) with 100-ll
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injection volume. The lower limit of detection
was 0.35 lg/ml and the lower limit of quantifi-
cation was 2.55 lg/ml.
Statistical analysis of data was done using
two-way analysis of variance (ANOVA) with
IBM SPSS V.22 (SPSS Inc., Chicago, IL, USA).
Fig. 2 Schematic design of in vitro model setting
Fig. 1 Schematic design of the six different nebulizers studied
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Data modeling using Design Expert 7.0.0 (Sta-
t-Ease Inc., Minneapolis, MN, USA) with model
inputs (nebulizer type and nebulizer design)
and outputs (inhalation and nebulizer chamber
amounts of salbutamol). Input data were enco-
ded numerically, for nebulizers, JN (1) and VMN
(2); JN designs, JN A (0.1), JN B (0.2), and JN C
(0.3); and VMN designs Solo (0.1), Pro (0.2), and
Nivo (0.3).
The analysis in this article is based on pre-
viously conducted in vitro studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
Table 1 and Fig. 3 show the amount of salbuta-
mol recovered from each inhalation filter (in-
halable dose) and nebulizer chamber (residual
dose) of the six nebulizers expressed as mean
(SD) lg.
The three VMNs studied had a significantly
higher (p\0.001) amount of salbutamol
deposited on the inhalation filter (inhaled dose)
and a significantly lower amount of salbutamol
remaining in the nebulizer chamber (residual
dose) than the three studied JN (p\0.001).
Designs of jet nebulizers different design had
a significant effect on inhaled dose and residual
dose (p\0.05). JN C had the highest emitted
dose while JN A had the lowest one (p\0.05).
However, there were no significant differences
between the three VMNs studied, as shown in
Table 1 and Fig. 3.
Modeling of the data showed a successful
model for validation of current data and could
help in the prediction of further data. This is
indicated by low design stander error as shown
in Fig. 4 and the model high predicted correla-
tion coefficient (R2), as shown in Table 2. Simi-
lar to statistical comparison, data modeling
showed the significant effect of nebulizer design
on JN efficacy. Response surface plots of the
effect of nebulizer type and design on inhaled
dose is shown in Fig. 5 and on residual dose in
Fig. 6.
Figures 5 and 6 show that no change was
observed by changing the type of the VMN but



































































































































































in the inhaled dose and residual dose. Figures 5
and 6 also show that the VMN had a much
better inhaled dose and lower residual dose
than JN. The emitted dose from JN decreased
from the highest value for JN C to the lowest of
JN A, showing the role of nebulizer design on
inhalable dose, while the upper border of Fig. 5
did not show any obvious decline, indicating
that efficacy of VMN was not affected by the
nebulizer designs. Also, the upper border of
Fig. 6 represents the amounts of drug that
remained in the JN chambers, which were
higher than those of VMNs, which are shown at
the lower border of Fig. 6.
Fig. 3 Mean (SD)
inhalable dose and
residual dose in lg
from the six different
nebulizers studied




Table 2 Model ANOVA statistics for inhalation and nebulizer chamber model






Standard deviation 216.71 R-squared 0.8763
Mean 1080.17 Adjusted R squared 0.8697
CV% 20.06 Predicted R squared 0.8558
Adequate precision 22.689
Nebulizer chamber
Model 210.87 \ 0.0001
Nebulizer 619.54 \ 0.0001
Design 5.73 0.0201
Standard deviation 432.90 R squared 0.9187
Mean 1882.18 Adjusted R squared 0.9143
CV% 23.00 Predicted R squared 0.9055
Adequate precision 28.212
CV coefﬁcient of variation
Fig. 5 Response sur-








VMNs again showed much better efficiency in
aerosol delivery compared to JN, resulting in
higher inhaled dose (p\0.001) and lower
residual dose (p\0.001) [13–15].
Significantly difference inhaled dose from
different JN designs (p\0.05) demonstrate the
effect of JN design on efficacy of nebulizer,
which could affect therapeutic outcomes. JN C
had the highest inhaled dose compared to JN A
and JN B (p\0.05) and JN B was more efficient
than JN A (p\0.05). It was noted for JN A,
which has the lowest emitted dose, that the flat
end of the nozzle cover had a role in low effi-
cacy because large drops of the drug were settled
on the upper face, preventing them from
entering the area between the nozzle and its
cover [6]. Therefore, different JN designs have a
great role in nebulizer efficacy, as previously
shown in a study carried out on the available
brands of JN in France. They showed that dif-
ferent nebulizer brands had different efficacy on
delivering aerosol to cystic fibrosis patients [12].
Their findings support our results as well as the
other study, which showed that even different
batches of the same JN resulted in different
inhaled doses [16], especially with small fill
volume, which is considered a very important
factor affecting aerosol delivery due to residual
dose remaining in the nebulizer chamber at the
end of nebulization [4, 5, 17]. This is why we
used a fixed low volume of salbutamol (1 ml) for
all the nebulizers to evaluate efficacy of each
device on deliver optimum amounts of drug
with low volumes. Therefore, we recommend
increasing the fill volume of the JN to overcome
this difference.
However, there was no significant effect of
nebulizer change on inhaled dose from VMNs
which have a different operating mechanism
from JN. JN aerosolizes by the effect of air
pressure that passes through a nozzle fixed in
the nebulizer chamber. The velocity of the
passing gas causes the pressure to drop in the
area between the nozzle and the nozzle cover,
which is called the ‘‘Venturi effect’’ [6]. This
drop in pressure leads the respirable solution to
path through this area around the nozzle
upward by Bernoulli effect forming a thin layer
of solution that converts to fine particle then is
emitted from the nebulizer chamber toward the
patient [6]. Large droplets will be settled on the
nebulizer chamber wall or nozzle cover to be
returned to the reservoir solution.
However, the vibrating mesh plat consists of
a piezoelectric element fixed at the bottom of
the nebulizer chamber that vibrates in response
to electric current [6, 18, 19]. Upward and
downward movement of vibrating plat convert
respirable solution in nebulizer chamber to fine
droplets emitted out toward patient [20].
According to this mechanism of operation,
Fig. 6 Response sur-






which is the same for all VMNs brands, vari-
ability between different VMNs designs could be
of less significance on aerosol delivery com-
pared to JN, which is affected by the shape or
size of the nozzle and also the shape of the
nebulizer chamber. So the interchange of the
VMNs, but not JNs, is possible with no fear of
variation of the delivered dose [21].
When looking at the modeling results, the
models’ F values of inhaled dose and residual
dose were 132.29 and 210.87, respectively. This
implies that these models are significant and
could be used successfully for validation and
prediction of optimization of aerosol delivery,
as there is only a 0.01% chance that a ‘‘model
F value’’ could occur due to noise. Also, a low
standard error of model, shown from Fig. 4,
reflects a non-significant lack of fit. Values of
‘‘Probability [F’’ less than 0.05 indicate the
model terms are significant. So, nebulizers, and
nebulizers designs interation are significant
model terms. The ‘‘predicted R squared’’ of
0.8558 and 0.9055 are in reasonable agreement
with the ‘‘adjusted R squared’’ of 0.8697 and
0.9143 for inhalation and nebulizer chamber,
respectively [21, 22]. ‘‘Adequate precision’’
measures the signal-to-noise ratio. Ratios of
22.689 and 28.212 indicate an adequate signal.
Modeling response surface plots (Figs. 5 and
6) support our finding with a very sharp change
in the inhaled dose and residual dose by
changing the design of the JN. The sharp
change observed with JNs was not observed
with changing the VMN type [21], however,
changing from JN to VMN resulted in much
better aerosol delivery. Therefore, residual dose
as well as inhalable dose emitted from nebuliz-
ers studied indicated the presence of a signifi-
cant effect of designs in JN only.
CONCLUSIONS
Nebulizer design significantly affected aerosol
delivery by jet nebulizers with no significant
effect when using vibrating mesh nebulizers of
different designs. These findings were supported
by statistical comparison and modeling, which
proved to be a good tool for optimizing aerosol
delivery from nebulizers in NIV.
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